Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Shares Outstanding (Weighted Average) (2018 - 2025)

Summit Therapeutics' Shares Outstanding (Weighted Average) history spans 8 years, with the latest figure at $743.4 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 2.31% year-over-year to $743.4 million; the TTM value through Sep 2025 reached $743.4 million, up 2.31%, while the annual FY2024 figure was $718.5 million, 15.96% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $743.4 million in Q3 2025 per SMMT's latest filing, roughly flat from $742.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $743.4 million in Q3 2025 to a low of $82.8 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $447.9 million, with a median of $619.6 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 397.94% in 2023, then increased 1.03% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $131.7 million in 2021, then surged by 46.78% to $193.3 million in 2022, then skyrocketed by 220.5% to $619.6 million in 2023, then increased by 15.96% to $718.5 million in 2024, then grew by 3.46% to $743.4 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Shares Outstanding (Weighted Average) are $743.4 million (Q3 2025), $742.6 million (Q2 2025), and $738.1 million (Q1 2025).